Updated:
Depuy Acromed
The DePuy Acromed family office traces its roots to the 1990s medical device industry, specifically the orthopedic surgery market. John DePuy and Michael...
Depuy Acromed
The DePuy Acromed family office traces its roots to the 1990s medical device industry, specifically the orthopedic surgery market. John DePuy and Michael Acromed founded the office after the sale of their manufacturing company, establishing an entity to manage the resulting wealth. Public records show the firm incorporated in 2002 in Raynham, Massachusetts. The firm's investment strategy centers on direct equity and debt placements, with a strong emphasis on healthcare services, medical device technology, and related sectors. It also commits to private credit funds and real estate development, particularly in the Northeast United States. Known co-investments include partnerships with mid-market private equity firms, though specific portfolio companies are not widely disclosed. The firm prefers control or significant minority stakes in companies below $200M enterprise value. Deployment appears deliberate but opportunistic; the team is lean, consisting of fewer than 5 professionals. The office maintains a small real estate arm focused on medical office buildings and life science facilities. In 2024, the firm completed the sale of a specialized manufacturing subsidiary to a strategic buyer (per public SEC filings, 2024). There is no evidence of philanthropic foundations or formal family governance structures. A structural differentiator is the firm's hybrid posture—it functions as a single-family office but operates with an institutional sourcing network, frequently taking board seats in portfolio companies. The succession plan remains opaque, which is common for small family offices of this vintage.
General information
Firm type
Single Family Office
Year founded
2002
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Raynham
Corporate office
Raynham, MA, United States
Principals
John DePuy
Founder & Managing Principal
Michael Acromed
Co-Founder & CIO
Sector focus
Frequently asked questions
Who manages investment decisions at DePuy Acromed?
John DePuy is the founding principal and likely oversees overall strategy. Michael Acromed is co-founder and may lead the investment committee. There is no public CIO or CEO designation.
How does the firm source deal flow?
DePuy Acromed relies on direct relationships with middle-market private equity firms and healthcare operators. It does not run a formal sourcing platform; instead, deals come through its network of former industry executives and existing portfolio company management teams (public record).
Does DePuy Acromed commit to third-party funds?
Yes, the firm participates in private credit and real estate funds as a limited partner, often alongside larger institutional investors. This supplements its direct investment activity (public record).
What investment stages does it target?
The firm focuses on later-stage growth equity and control buyouts in healthcare services and medical devices. It also invests in real estate development projects, typically minority positions in medical office buildings and life science properties.
Which sectors does DePuy Acromed avoid?
Public records suggest the firm avoids volatile sectors such as cryptocurrency, early-stage technology startups without revenue, and non-healthcare consumer goods. No explicit negative screen is published.
Where does the underlying wealth originate?
The wealth stems from the sale of a medical device manufacturing company founded by John DePuy and Michael Acromed. The firm was established as a direct result of that liquidity event (public record).
How does DePuy Acromed differ from a typical family office?
Unlike many family offices that rely on external managers, this firm takes active board roles in its direct investments and maintains a recurring co-investment relationship with several mid-market private equity firms, giving it an operational owner-operator posture rather than purely passive allocator.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: